Eli Lilly Tirzepatide Diabetes Treatment

Cipla, Eli Lilly and Yurpeak

Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug Yurpeak

In an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now available for patients in India. With Cipla handling nationwide distribution,

Medical Dialogues · 2d

Eli Lilly's Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal

· 3d

Cipla to market Eli Lilly’s weight loss and diabetes drug Mounjaro in India, under a different brand name

4don MSN

3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

AOL

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Cipla, Eli Lilly and Yurpeak

3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Trending now